XML 30 R13.htm IDEA: XBRL DOCUMENT v3.25.0.1
Note C - Segment Information
 12 Months Ended
Dec. 31, 2024
Notes to Financial Statements  
Segment Reporting Disclosure [Text Block]

C.

Segment Information

 

Zevra manages its business activities on a consolidated basis and operates as a single operating segment dedicated to the research and development, manufacturing, commercialization and sale of innovative medicines and therapies. The Company primarily derives its revenue from reimbursements received from the EAP, AZSTARYS License Agreement, OLPRUVA product sales, MIPLYFFA product sales, and consulting arrangements. The accounting policies of the segment are the same as those described in Note B.

 

Zevra's CODM is the Company's Chief Executive Officer, Neil F. McFarlane. The CODM uses net loss, as reported in the Company's Consolidated Statements of Comprehensive Loss, in evaluating performance of its segment and determining how to allocate resources of the Company as a whole, including investing in its research and development, commercialization efforts, and acquisition strategy. The CODM does not review assets in evaluating the results of the segment, and therefore, such information is not presented.

 

 The following table presents the operating results of the Company's segment:

 

 

  

December 31,

  

December 31,

 
  

2024

  

2023

 

Total revenues

 $23,612  $27,461 

Less significant segment expenses:

        

Research and development directly identified to programs

  22,532   30,083 

Research and development not directly identified to programs

  19,562   9,723 

Selling, general and administrative directly identified to programs

  18,094   7,770 

Selling, general and administrative not directly identified to programs

  36,775   26,544 

Other segment items:

        

Income tax expense

  15,371   - 

Interest income

  (3,159)  (4,527)

Depreciation and amortization expense

  6,389   1,006 

Interest expense

  7,351   1,501 

Other expense, net(a)

  6,208   1,410 

Segment net loss

 $(105,511) $(46,049)
         

 

(a) Other expense, net included in segment net loss includes foreign currency exchange gains and losses, cost of product revenue (excluding intangible asset amortization), fair value adjustment related to warrant and CVR liabilities, fair value adjustment related to investments, and other overhead expense.